Clincosm LogoSign in Get a demo

A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus

Sponsor
Natural Wellness Egypt (Industry)
Overall Status
Completed
CT.gov ID
NCT05347329
Collaborator
(none)
197
Enrollment
1
Location
3
Arms
14.7
Actual Duration (Months)
13.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This was a randomized, double blind, placebo-controlled, Three-arm, multicenter, parallel groups, interventional phase II clinical trial evaluating the efficacy, and safety of a herbal medicinal product of dried roots of Eurycoma longifolia Jack (Tongkat Ali) and dried tuberous roots of Lepidium meyenii (Maca) for the improvement of sexual well-being and quality of life in men.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Tongkat Ali Maca Plus
 N/A

Detailed Description

Sexual health is fundamental to the physical and emotional health and wellbeing of individuals, couples and families, and to the social and economic development of communities and countries" says the World Health Organization. Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse. ED may affect physical and psychosocial health and may have a significant impact on the quality of life (QoL) of sufferers and their partners. It is a common cross-cultural condition in developing and industrialized countries, but its true incidence is probably underestimated owing to the embarrassment of seeking help.

Data from the Massachusetts Male Aging Study (MMAS), a community based, random sample prospective observational survey of non-institutionalized men aged 40-70years, found that 52% of men reported erectile dysfunction. ED is commonly classified into three categories based on its etiology. These include organic, psychogenic and mixed ED. However, this classification should be used with caution since most cases are actually of mixed etiology. It is therefore suggested to use the term primary organic or primary psychogenic. Phosphodiesterase type 5 inhibitors are the standard care and treatment for most mild to moderate ED patients. Most common side effects of phosphodiesterase-5 inhibitors are in the form of headache, visual abnormalities, nasal congestion, dyspepsia, and myalgia.

Enhancing healthy sexuality is possible with the use of natural plants and nutrients. In Asia, men consider herbal medicine to be a reliable treatment for improving overall wellbeing, including sexual wellbeing.

In Malaysia the root of Eurycoma longifolia, known traditionally as Tongkat Ali, is one of the most popular herbs used for well-being. It is used to increase fertility and sexual power and is claimed to improve strength and power during sexual activities. Many studies carried out on rats and mice have found that administration of E. longifolia extracts increases the sexual arousal and motivation and frequency of sexual activity. These effects are similar to those caused by administration of testosterone, although the effect of Tongkat Ali is not as strong. Tongkat Ali is reputed to increase testosterone effect. It was found to have androgenic effects in male rats, either directly or indirectly, such as increasing the weight of sexual accessories. The effect of this plant is dependent upon the dose; whether or not it contributes significantly to the aphrodisiac qualities of Tongkat ali can only be established with more research.

A recent systematic review with meta-analysis concluded that the herbal extract of Tongkat Ali may have clinical effect on erectile function. However, more efficacy trials are warranted to further support current evidence.

Maca (Lepidium meyenii) is an Andean plant that belongs to the brasslike (mustard) family. It has been used for centuries in enhancing the fertility in humans and animals. Preparations from the Maca root have been reported to improve sexual function in healthy populations. There is a hypothesis questioning if Maca is effective in improving sexual function. Spermatogenic and fertility-enhancing activities are suggested through animal experiments. Some in-vivo studies have shown that Maca may improve sexual behavior and enhance androgen-like effects in rats. Recent clinical trials have also suggested significant effects of Maca for increasing sperm count and mobility and improving sexual function in humans.

However, these data are insufficient for determining whether Maca is clinically effective.

The results of a recent systematic review provide suggestive evidence for the effectiveness of Maca in improving semen quality.

By today, robust clinical data on Tongka tali and Maca safety and efficacy is not sufficient. This study was conducted to evaluate Efficacy and Safety of Tongkat Ali Maca Plus for the improvement of sexual well-being and quality of life in men with mild to moderate erectile dysfunction.

Study Design

Study Type:
Interventional
Actual Enrollment :
197 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This was a randomized, double blind, placebo-controlled, Three-arm, multicenter, parallel groups, interventional phase II clinical trial evaluating the efficacy, and safety of a herbal medicinal product of dried roots of Eurycoma longifolia Jack (Tongkat Ali) and dried tuberous roots of Lepidium meyenii (Maca) for the improvement of sexual well-being and quality of life in men.This was a randomized, double blind, placebo-controlled, Three-arm, multicenter, parallel groups, interventional phase II clinical trial evaluating the efficacy, and safety of a herbal medicinal product of dried roots of Eurycoma longifolia Jack (Tongkat Ali) and dried tuberous roots of Lepidium meyenii (Maca) for the improvement of sexual well-being and quality of life in men.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The arms randomization was performed using Interactive web response system (IWRS).
Primary Purpose:
Treatment
Official Title:
A Phase II, Randomized, Double Blind, Placebo-Controlled, Three-arm, Multi-center Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus for the Improvement of Sexual Well-being and Quality of Life in Men
Actual Study Start Date :
Sep 10, 2019
Actual Primary Completion Date :
Nov 30, 2020
Actual Study Completion Date :
Nov 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control Arm 1

Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient), administered orally once daily on empty stomach with plenty of water.

Dietary Supplement: Tongkat Ali Maca Plus
Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
Other Names:
  • Placebo Comparator: Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient)

    		•
    Experimental: 400 mg Tongkat Ali+ 200 mg Maca (Experimental Arm 2)

    The content of 2 capsules of Tongkat Ali Maca (600 mg of active ingredient), Plus is equally distributed and inserted into 3 capsules size 1 (low dose), administered orally once daily with plenty of water.

    Dietary Supplement: Tongkat Ali Maca Plus
    Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
    Other Names:
  • Placebo Comparator: Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient)

    		•
    Experimental: 600 mg Tongkat Ali+ 300 mg Maca ( Experimental Arm 3)

    The content of 3 capsules of Tongkat Ali Maca Plus (900 mg of active ingredient), is equally distributed and inserted into 3 capsules size 1 (high dose), administered orally once daily with plenty of water.

    Dietary Supplement: Tongkat Ali Maca Plus
    Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
    Other Names:
  • Placebo Comparator: Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient)

    		•

    Outcome Measures

    Primary Outcome Measures

    1. To explore the effect of Tongkat Ali and Maca dried roots extracts (Tongkat Ali Maca Plus) on sexual performance [12 weeks]

      sexual performance will be measured by the change in the International Index of Erectile Function questionnaire score

    2. To explore the safety of Tongkat Ali Maca Plus as measured by the occurrence of adverse events [12 weeks]

      the safety of Tongkat Ali Maca Plus will be measured by the occurrence of adverse events

    Secondary Outcome Measures

    1. To explore the effect of Tongkat Ali Maca Plus on serum levels of free and total testosterone. [12 weeks]

      To explore the effect of Tongkat Ali Maca Plus on serum levels of free and total testosterone.

    2. To explore the effect of Tongkat Ali Maca Plus on sexual wellbeing [12 weeks]

      sexual wellbeing will be measured by the change in Erectile Dysfunction Effect on Quality of Life questionnaire score

    3. To explore the effect of Tongkat Ali Maca Plus on quality of life [12 weeks]

      quality of life measured by the change in World Health Organization Quality-of-Life Scale questionnaire score

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years to 65 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Male aged between 35 and 65 years.

    2. Patients with mild, mild to moderate or moderate Erectile Dysfunction as defined by International Index of Erectile Function-5 (IIEF-5) score ≥8 and ≤21.

    3. Patients with decreased libido according to self-report.

    4. Patients in a stable heterosexual relationship for at least 6 months and willing to continue efforts at sexual activity for the duration of the study.

    5. Patients willing to stop any other medications for erectile dysfunction throughout study duration.

    6. Able and willing to provide written informed consent

    Exclusion Criteria:

    1. Patients with history of prostate cancer

    2. Patients with free: total prostate-specific antigen (PSA) ratio ≤ 0.15 or PSA > 4 ng/ml.

    3. Patients with acute or chronic prostatitis during the screening visit.

    4. Patients with Penile anatomical abnormalities

    5. Patients with pregnant partners or partners planning to become pregnant during the study.

    6. Clinically significant abnormality of physical examination that from investigator's point of view may interfere with study treatment.

    7. Any medical or psychological condition or social circumstances that would impair subject's ability to participate reliably in the study.

    8. Testosterone implant during 6 months prior to screening.

    9. Subjects for whom sexual activity is inadvisable.

    10. Uncontrolled hypertension according to ESC/ESH guidelines.

    11. Uncontrolled hypotension as defined by average SBP < 90 mmHg or average DBP <60 mmHg.

    12. Uncontrolled diabetes mellitus as defined by HbA1c ≥ 7%.

    13. Alcohol or substance abuse or dependence within the past six months.

    14. Recent major relationship changes, disruption, or turmoil

    15. Patients with any major psychiatric disorder (including major depression or schizophrenia).

    16. Patients with a history of medical conditions or procedures which may cause sexual dysfunction, including: heart failure, serious psychiatric diseases, endocrinological diseases, active cardiovascular diseases, peripheral vascular disease, spinal cord injury, pelvic fracture, brain injuries or tumors, multiple sclerosis.

    17. Consumption of medications which may alter sexual performances e.g., intake of hormone therapy, anti-depressants, H2 blockers, nitrates, anti- androgens or chemotherapy.

    18. Patients with Allergy or allergic history to any of the drug components.

    19. Patients with history of HIV infection or current infection with any sexually transmitted diseases.

    20. Receipt of an investigational drug within 6 months prior to screening, or active enrolment in another investigational medication or device trial.

    21. Patients with any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial.

    22. Inability to understand and cooperate with the investigators or to give valid consent.

    23. Patients with BMI > 40 Kg/m2 or BMI < 18.5 Kg/m2.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of Medicine, Menoufia University/ Egypt Shibīn Al Kawm Menoufia Egypt

    Sponsors and Collaborators

    • Natural Wellness Egypt

    Investigators

    • Principal Investigator: Prof Dr. Mohamed badreldin, MD, Menoufia University/ Egypt

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Natural Wellness Egypt
    ClinicalTrials.gov Identifier:
    NCT05347329
    Other Study ID Numbers:
    • TongMac 19052016
    First Posted:
    Apr 26, 2022
    Last Update Posted:
    May 3, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Natural Wellness Egypt
    Tongkat Ali and Maca
    Additional relevant MeSH terms:
    Erectile Dysfunction

    Study Results

    No Results Posted as of May 3, 2022